CY1109687T1 - Παραγωγα 2-φαινυλπροπιονικου οξεος και φαρμακευτικες συνθεσεις που τα περιεχουν - Google Patents

Παραγωγα 2-φαινυλπροπιονικου οξεος και φαρμακευτικες συνθεσεις που τα περιεχουν

Info

Publication number
CY1109687T1
CY1109687T1 CY20091101318T CY091101318T CY1109687T1 CY 1109687 T1 CY1109687 T1 CY 1109687T1 CY 20091101318 T CY20091101318 T CY 20091101318T CY 091101318 T CY091101318 T CY 091101318T CY 1109687 T1 CY1109687 T1 CY 1109687T1
Authority
CY
Cyprus
Prior art keywords
treatment
prevention
compounds
pharmaceutical compositions
compositions containing
Prior art date
Application number
CY20091101318T
Other languages
English (en)
Inventor
Marcello Allegretti
Riccardo Bertini
Maria Candida Cesta
Marco Mosca
Original Assignee
Dompe' S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe' S.P.A. filed Critical Dompe' S.P.A.
Publication of CY1109687T1 publication Critical patent/CY1109687T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Παράγωγα του 4-(τριφθορομεθανοσουλφονυλοξυφαινυλ) οξέος προπιοναμίδιου και οι φαρμακευτικές συνθέσεις που περιέχουν τέτοιες ενώσεις είναι χρήσιμες για την αναστολή της χημειοτακτικής ενεργοποίησης των ουδετερόφιλων (ΡΜΝ λευκοκύτταρα) που προκαλείται από την αλληλεπίδραση της ιντερλευκίνης-8 (IL-8) με τους υποδοχείς μεμβράνης CXCR1 και CXCR2. Οι ενώσεις χρησιμοποιούνται για την πρόληψη και την αντιμετώπιση παθολογικών καταστάσεων που προκύπτουν από την αναφερθείσα ενεργοποίηση. Αξίζει να σημειωθεί ότι αυτοί οι μεταβολίτες δεν διαθέτουν δράση αναστολής της κυκλοοξυγενάσης και είναι ιδιαίτερα χρήσιμοι στην αντιμετώπιση των παθολογικών καταστάσεων που εξαρτώνται από τα ουδετερόφιλα, όπως η ψωρίαση, η ελκώδης κολίτιδα, το μελάνωμα, η χρόνια αποφρακτική πνευμονοπάθεια (COPD), φυσαλιδώδες πεμφιγοειδές, ρευματοειδής αρθρίτιδα, ιδιοπαθής ίνωση, σπειραματονεφρίτιδα και για την πρόληψη και την αντιμετώπιση των ζημιών που προκαλούνται από την ισχαιμία και την επαναιμάτωση.
CY20091101318T 2004-03-23 2009-12-18 Παραγωγα 2-φαινυλπροπιονικου οξεος και φαρμακευτικες συνθεσεις που τα περιεχουν CY1109687T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101202 2004-03-23
EP05729779A EP1776336B1 (en) 2004-03-23 2005-03-21 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
CY1109687T1 true CY1109687T1 (el) 2014-08-13

Family

ID=34970877

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101318T CY1109687T1 (el) 2004-03-23 2009-12-18 Παραγωγα 2-φαινυλπροπιονικου οξεος και φαρμακευτικες συνθεσεις που τα περιεχουν

Country Status (21)

Country Link
US (2) US8039656B2 (el)
EP (1) EP1776336B1 (el)
JP (1) JP4871257B2 (el)
CN (2) CN1934077B (el)
AT (1) ATE444286T1 (el)
AU (1) AU2005223402B2 (el)
CA (1) CA2553705C (el)
CY (1) CY1109687T1 (el)
DE (1) DE602005016937D1 (el)
DK (1) DK1776336T3 (el)
ES (1) ES2333445T3 (el)
HK (2) HK1101392A1 (el)
HR (1) HRP20090681T1 (el)
ME (1) ME01763B (el)
NO (1) NO337685B1 (el)
PL (1) PL1776336T3 (el)
PT (1) PT1776336E (el)
RS (1) RS51109B (el)
RU (1) RU2375347C2 (el)
SI (1) SI1776336T1 (el)
WO (1) WO2005090295A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629935C (en) * 2005-11-24 2016-01-19 Dompe S.P.A. (r)-arylalkylamino derivatives and pharmaceutical compositions containing them
AU2007253424B2 (en) * 2006-05-18 2013-03-07 Dompe' Farmaceutici S.P.A. (2R)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them
EP2094638B1 (en) * 2006-12-19 2012-08-08 Dompe' S.P.A. 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2316820A1 (en) 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
MD480Z5 (ro) * 2011-07-07 2012-09-30 Эльвира АНДОН Metodă de tratament al colitei ulceroase nespecifice acute
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
EP3117835A1 (en) * 2015-07-14 2017-01-18 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment of certain urological disorders
MX2018008614A (es) * 2016-01-15 2018-11-19 Dompe Farm Spa Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.
EP3192504A1 (en) 2016-01-15 2017-07-19 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
CN109890364B (zh) * 2016-10-03 2023-10-17 儿童医疗中心公司 糖尿病肾病的预防和治疗
EP3342407A1 (en) * 2017-01-03 2018-07-04 Dompé farmaceutici S.p.A. Il-8 inihibitors for use in the treatment of some urological disorders
EP3409277A1 (en) * 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
EP3868368A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
EP3868369A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
US20230141355A1 (en) 2020-03-26 2023-05-11 Dompe' Farmaceutici Spa Cxcl8 inhibitors for use in the treatment of covid-19
EP3884932A1 (en) 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP4008325A1 (en) 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP4052702A1 (en) 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL335052A1 (en) * 1997-01-29 2000-03-27 Pfizer Derivatives of sulphonylurea and their application in regulating activity of interleukin-1
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
ITMI20010395A1 (it) * 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
ITMI20012025A1 (it) * 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
HUE026285T2 (en) * 2003-02-06 2016-05-30 Dompe Farm Spa 2-arylacetic acid compounds and their derivatives and pharmaceutical compositions containing them
CA2539842C (en) * 2003-09-25 2013-02-12 Dompe S.P.A. Amidines and derivatives thereof and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ES2333445T3 (es) 2010-02-22
CA2553705C (en) 2012-12-11
EP1776336B1 (en) 2009-09-30
CN1934077B (zh) 2010-09-29
ME01763B (me) 2010-10-31
WO2005090295A2 (en) 2005-09-29
JP4871257B2 (ja) 2012-02-08
RU2006137272A (ru) 2008-04-27
DE602005016937D1 (de) 2009-11-12
CN1934077A (zh) 2007-03-21
HK1101392A1 (en) 2007-10-18
PT1776336E (pt) 2009-12-18
US20090203740A1 (en) 2009-08-13
HRP20090681T1 (hr) 2010-02-28
ATE444286T1 (de) 2009-10-15
US20120004264A1 (en) 2012-01-05
AU2005223402B2 (en) 2011-07-21
EP1776336A2 (en) 2007-04-25
CA2553705A1 (en) 2005-09-29
DK1776336T3 (da) 2010-01-18
AU2005223402A1 (en) 2005-09-29
NO20064766L (no) 2006-10-20
NO337685B1 (no) 2016-06-06
US8293788B2 (en) 2012-10-23
RU2375347C2 (ru) 2009-12-10
US8039656B2 (en) 2011-10-18
SI1776336T1 (sl) 2010-01-29
WO2005090295A3 (en) 2005-10-27
CN101912382A (zh) 2010-12-15
CN101912382B (zh) 2012-11-21
RS51109B (sr) 2010-10-31
HK1148219A1 (en) 2011-09-02
JP2007530505A (ja) 2007-11-01
PL1776336T3 (pl) 2010-06-30

Similar Documents

Publication Publication Date Title
CY1109687T1 (el) Παραγωγα 2-φαινυλπροπιονικου οξεος και φαρμακευτικες συνθεσεις που τα περιεχουν
NO20054672D0 (no) Sulfonsyrer, derivater derav og farmasoytiske prepater omfattende slike forbindelser
NO20054017L (no) 2-aryl-eddiksyrer, deres derivater og farmasoytisk sammensetninger som inneholder dem
DK1856045T3 (da) 1-eddikesyreindolderviater med PGD2-antagonisteffekt
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
Schrøder et al. The identification of AF38469: an orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin
ATE449082T1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
MXPA04004744A (es) Acidos 2-aril-propionicos y composiciones farmaceuticas que contienen a los mismo.
Gilbert et al. N-((8-Hydroxy-5-substituted-quinolin-7-yl)(phenyl) methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2)
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister
George et al. Discovery of thieno [2, 3-c] pyridines as potent COT inhibitors
Walker et al. Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase
DE602006007210D1 (de) Metaboliten aus 2-arylpropionsäure-derivaten und pharmazeutische zusammensetzungen damit
Miller et al. Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas—the effect of capping the distal basic piperidine nitrogen
YU62801A (sh) Derivati 4-heterociklilsulfonamidil-6-metoksi-5-(2-metoksi- fenoksi)-2-piridil- piridimina, njihovo dobivanje i primena kao antagonisti endotelinskih receptora
Laliberté et al. Discovery of a series of aryl-N-(3-(alkylamino)-5-(trifluoromethyl) phenyl) benzamides as TRPA1 antagonists
Yokokawa et al. Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000–2008
Wei et al. CCR5 receptor antagonists: Discovery and SAR study of guanylhydrazone derivatives
Shishido et al. Synthesis of benzamide derivatives as TRPV1 antagonists